Clinical Trial Update: FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

An early-phase trial evaluating EVER4010001, an FGFR4 inhibitor, in combination with pembrolizumab for advanced solid tumors is in Phase 1/Phase 2 with status u…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• EVER4010001 (FGFR4 inhibitor)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: EverNov Medicines (Zhuhai Hengqin) Co., Ltd | Conditions: Advanced Solid Tumors | Phase 1, Phase 2 | Status: UNKNOWN